Activity and functional significance of the renal kallikrein-kinin-system in polycystic kidney disease of the rat  by Braun, Claude et al.
Kidney International, Vol. 61 (2002), pp. 2149–2156
Activity and functional significance of the renal kallikrein-
kinin-system in polycystic kidney disease of the rat
CLAUDE BRAUN, THOMAS KLEEMANN, ULRICH HILGENFELDT, UDO RIESTER, PETER ROHMEISS,
and FOKKO J. VAN DER WOUDE
V. Department of Medicine (Nephrology/Endocrinology/Rheumatology), University Hospital Mannheim, University of
Heidelberg, Mannheim, and Institute of Pharmacology, University of Heidelberg, Heidelberg, Germany
Activity and functional significance of the renal kallikrein- Autosomal dominant polycystic kidney disease
kinin-system in polycystic kidney disease of the rat. (ADPKD) is one of the most common genetic disorders
Background. The kallikrein-kinin-system is a complex multi- worldwide, with a frequency of 1 in 1000 in the general
enzymatic system that has been implicated in the control of
population. It is the cause of approximately 10% of end-systemic blood pressure, glomerular filtration rate, and protein-
stage renal failure in patients undergoing chronic renaluria. The present study investigated its functional role in rat
polycystic kidney disease (PKD), which is characterized by pro- replacement therapy [1]. Morphologically it is character-
gressive renal failure and proteinuria in the absence of systemic ized by the formation of multiple cysts and considerable
hypertension and stimulated renin-angiotensin-system. enlargement of both kidneys. The clinical course is char-
Methods. Kallikrein and bradykinin levels were measured
acterized by progressive loss of renal function in 50%in plasma and urine of rats with polycystic kidneys and com-
to 75% of affected patients becoming manifest generallypared to non-affected controls (SD) and rats with reduced
during the fourth to fifth decade of life. Although therenal mass. The functional relevance of the kallikrein-kinin
system (KKS) was assessed by the effects of a short-term genes responsible for most ADPKD cases have been
treatment with either a selective bradykinin (BK) B1-receptor identified [2, 3], the high degree of variability in the
antagonist (des-Arg9-[Leu8]-BK), a B2-receptor antagonist clinical course of patients is not well understood.
(HOE 140), an angiotensin converting enzyme inhibitor (rami-
Knowledge of factors that modulate the course of re-pril), or an angiotensin II-receptor blocker (HR 720) on sys-
nal disease in these patients would therefore be of prog-temic and renal parameters.
nostic value, and their identification could help establishResults. Urine levels of kallikrein were increased threefold
in 9-month-old PKD, and BK excretion was increased tenfold therapeutical strategies aimed at delaying the progres-
in 3-month and 30-fold in 9-month-old PKD compared to age- sion of renal failure in subjects with ADPKD. Impor-
matched SD rats. Blood pressure in 9-month-old PKD rats was tantly, hypertension and proteinuria have been impli-decreased to the same degree by ramipril and HR 720. In
cated in a more severe disease progression in ADPKDcontrast, only ramipril and HOE 140 significantly reduced pro-
patients [4–6]. This situation is, however, not unique toteinuria and albuminuria, independent from creatinine clear-
ance. This effect was accompanied by an increased excretion ADPKD, but is observed in a large number of kidney
of bradykinin. The B1 receptor antagonist had no influence on diseases. Lowering of arterial blood pressure and/or pro-
functional renal parameters. teinuria therefore remains a primary therapeutical goal.
Conclusions. The present study demonstrates an age-depen- In most of these diseases, the renin-angiotensin-systemdent activation of the renal KKS in rats with polycystic kidney
(RAS) plays a seminal role with respect to arterial hyper-disease. The bradykinin B2-receptor is involved in the patho-
tension, regulation of glomerular filtration rate (GFR),genesis of proteinuria, independent from systemic blood pres-
sure or creatinine clearance. The antiproteinuric effect of rami- development of proteinuria, and progression of chronic
pril in this model is angiotensin II-independent and related to renal failure. This concept has been demonstrated by
its influence on the renal KKS. the nephroprotective effect of pharmacological blockade
of the RAS in diabetic nephropathy [7], chronic allograft
nephropathy [8], and remnant kidney model [9], to name
only a few.Key words: bradykinin, PKD, reduced renal mass, HR 720, HOE 140,des-
Arg9-[Leu8]-bradykinin, ramipril, renin-angiotensin system, ADPKD. Biological effects of the RAS are not only directly
exerted by stimulation of angiotensin receptors, but areReceived for publication April 10, 2001
also the result of a complex interplay with a number ofand in revised form November 26, 2001
Accepted for publication February 5, 2002 other neurohumoral systems. One of them is the kalli-
krein-kinin-system (KKS). Comparable to the RAS, it 2002 by the International Society of Nephrology
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is composed of a series of potent vasoactive and proin- resected. Two weeks later, uninephrectomy of the right
flammatory molecules. An involvement in inflammatory kidney was performed. Animals were included in the
processes has been demonstrated both in vitro and in experiments at the age of 9 months.
vivo [10, 11]. The KKS also is activated in the advanced Rats were housed in metabolic cages twice for 24
stage of diabetic nephropathy in streptozotocin (STZ)- hours. During the first 24 hours urine was collected in
treated rats, a condition characterized by proteinuria and conventional tubes for determination of volume, creati-
decreased GFR [12]. Given the pronounced tubulointer- nine, sodium, protein, prekallikrein and kallikrein. A
stitial inflammation, the development of progressive re- blood sample was obtained for determination of creati-
nal failure and proteinuria, and the high incidence of nine, sodium, plasma renin activity, prekallikrein and
arterial hypertension, the KKS may be activated in pa- kallikrein. Blood pressure was measured by tail plethys-
tients with ADPKD. Thus far, however, this has not been mography, for which all animals had been previously
systematically investigated. trained. After 24 hours of rest the animals were again
The (cy/) rat is an animal model for ADPKD that housed in metabolic cages for 24 hours. Urine for deter-
shares many clinical and histological features with hu- mination of bradykinin was collected in tubes containing
man ADPKD [13]. It provides a suitable tool to investi- pure ethanol to arrest kinin formation and degradation.
gate the activity of the RAS and the KKS and their
Volume of ethanol in the collection tube was chosen
contribution to functional renal changes observed during
such that the concentration of urine at the end of thethe progression of renal failure. Their respective roles
collection period did not exceed 30% of total volume.in regulation of blood pressure and proteinuria were
investigated in the present study by short-term applica- Experimental protocol 2: Effects of ramipril, HR 720,
tion of an inhibitor of the angiotensin-converting enzyme HOE 140, and des-Arg9-[Leu8]-BK on renal function
(ACE), ramipril, a highly potent angiotensin II receptor in PKD
type 1 antagonist, HR 720, a selective BK-1 receptor
Three- and nine-month old PKD and SD were treatedantagonist (des-Arg9-[Leu8]-BK), and a selective brady-
for four days as follows: ramipril (2 mg/kg/day orally;kinin B2-receptor antagonist, HOE 140.
N  10, each group), HR 720 (10 mg/kg/day orally; N 
10, each group), HOE 140 (200 g SC injection twice
METHODS daily; N  10, each group), or des-Arg9-[Leu8]-bradyki-
Animals nin (250 g SC injection twice daily; N 10, each group)
in random order, with a two-week pause between eachMale homozygous unaffected (SD) and heterozygous
affected (PKD) Han:SPRD rats inbred to the 20th genera- four-day-treatment period. Drugs dissolved in drinking
tion in animal laboratories of the Center for Medical water were given to the rats every day during the study
Research at the University Medical Center Mannheim, period. Before and after the treatment period, blood
Germany, were used in the experiments. Animals were samples were obtained for determination of creatinine,
included in the study at the age of three and nine months. sodium and plasma renin activity. Urine was collected
Heterozygous rats were detected by manual palpation for determination of creatinine, sodium and protein. In
of the polycystic kidneys. All experiments were per- addition, urinary excretion of prekallikrein, kallikrein,
formed in conscious animals. Environmental conditions and bradykinin was determined before and after admin-
were kept constant: temperature 20C, air humidity 65% istration of each drug in 9-month-old PKD rats. Systolic
and a day/night cycle of 12 hours each. All rats were blood pressure was measured by tail plethysmography.
allowed free access to tap water and to a standard labora-
tory rat chow containing 19% protein (Altromin 1324, Measurement of sodium, creatinine and protein in
Lage, Germany). All animal experiments were con- serum and urine
ducted in accordance with the NIH Guide for the Care
Concentration of sodium in serum and urine was de-and Use of Laboratory Animals.
termined by use of a flame photometer (FLM-3; Radiom-
eter, Copenhagen, Denmark). Concentrations of creati-Experimental protocol 1: KKS and ADPKD
nine in serum and urine were measured by standardizedFive groups of animals were studied: group 1 (3-month-
colorimetric method (Hitachi Autoanalyser; Boehringerold PKD; N  15), group 2 (3-month-old SD; N  9),
Mannheim, Mannheim, Germany) and are expressed asgroup 3 (9-month-old PKD; N  26), group 4 (9-month-
mg/dL. Urinary protein concentration was determinedold SD; N 18), and group 5 (9-month-old SD with renal
following the method of Coomassie after centrifugationmass reduction; N 8). Renal ablation was performed as
of urine samples. Values for creatinine clearance andpreviously described [14]. Briefly, in 6-month-old SD
fractional sodium excretion were calculated using stan-rats, the left kidney was exteriorized through a dorsal
approach, and the upper and lower poles were surgically dard formulas.
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Measurement of albumin in urine Drugs
Ramipril, HR 720, and HOE 140 were a generous giftUrinary albumin was measured using a commercially
available kit (Nephrat; Exocell, Inc., Philadelphia, PA, from Professor B.A. Scho¨lkens (Hoechst AG, Frankfurt/
Main, Germany). Des-Arg9-[Leu8]-bradykinin was pur-USA). Urine samples were added to wells bearing anti-
rat-albumin on the solid phase. After 20 minutes at room chased from Sigma-Aldrich (Deisenhofen, Germany).
temperature rat-albumin-HRP conjugate was added (with-
Data calculation and statistical evaluationout washing), and a 45 minute incubation was completed.
Wells were washed sixfold with phosphate-buffered sa- All data are expressed as means  SEM. Differences
line (PBS; Gibco BRL, Paisley, Scotland, UK)/0.05% between groups were assessed by one-way analysis
Tween 20 (Sigma, St. Louis, MO, USA), and bound of variance (ANOVA) when appropriate. Two-tailed
conjugate was analyzed using TMB (3,3,5,5-tetrameth- paired t test with Bonferroni’s correction for adjustment
ylbenzidine) substrate solution. The chromogenic reac- for multiple testing was used after ANOVA for further
tion was stopped with diluted sulfuric acid, and color pair-wise comparison of the groups. Effects of treatment
intensity determined using a microplate reader set at regimens were assessed by the Student t test for paired
450 nm. values. Statistical significance was defined as P  0.05.
Measurement of plasmin renin activity
RESULTSPlasma renin activity was determined by radioimmu-
KKS and ADPKDnoassay as described by Fyhrquist et al [15]. Plasma renin
values are expressed as ng angiotensin-1 (Ang-1)/mL/h. Creatinine clearance was lower in 3-month-old PKD
compared to 3-month-old SD (P  0.05) and lower in
Measurement of prekallikrein and kallikrein in urine 9-month-old PKD and 9-month-old SD with renal abla-
Activity of prekallikrein and kallikrein was deter- tion compared to 9-month-old SD (P  0.05, respec-
mined following the method described by Amundsen et tively), whereas there was no difference between 9-
al [16]. The chromogenic peptide substrate H-D-Val- month-old PKD and rats with remnant kidney. Creati-
Leu-Arg-p-nitroanilide (S-2266; Haemochrom Diagnos- nine clearance was reduced in 9-month-old SD in com-
tika, Essen, Germany) was used in this assay, and extinc- parison to the young SD (P 0.05), as was the clearance
tion was measured photometrically at 405 nm. Each sam- in old PKD in comparison to young PKD rats (P  0.05;
ple was compared to a negative control sample in which Table 1).
kallikrein was inhibited by the addition of aprotinine Fractional sodium excretion did not differ between
(100 KIU/mL). Activity of kallikrein in urine was derived 3-month-old SD and PKD, but was significantly higher
from extinction difference between the two samples and in 9-month-old PKD compared to age-matched SD (P
expressed as units per liter (U/L). One unit is the amount 0.05). SD with reduced renal mass showed a significant
of kallikrein that converts 1 mol of substrate under higher fractional sodium excretion than 9-month-old
standardized conditions. PKD animals (P  0.05; Table 1).
Plasma renin activity did not differ between 3-month-
Measurement of prekallikrein and kallikrein in plasma old SD and PKD, whereas it was suppressed in 9-month-
Enzymatic activity of plasma prekallikrein and kalli- old PKD compared to both 9-month-old SD and rats
krein was determined with the amidolytic assay de- with reduced renal mass (P  0.01, respectively). Pro-
scribed by Gallimore and Friberger [17]. In this assay the teinuria did not differ between young SD and PKD,
chromogenic substrate H-D-Pro-Phe-Arg-p-nitroanilide but was significantly increased to the same level in both
(S2302; Haemochrom Diagnostika, Essen, Germany) 9-month-old PKD and rats with reduced renal mass in
was used. comparison to 9-month-old SD (P  0.01, respectively).
Albuminuria was significantly increased in PKD and ne-
Measurement of bradykinin in urine phrectomized rats compared to age-matched SD (P 
0.05, respectively).After ethanol extraction and high-pressure liquid
chromatography (HPLC) separation (ODP 50; Asahi- Systolic blood pressure did not significantly differ be-
tween the four groups of SD and PKD (although therePak) the concentration of bradykinin was measured us-
ing the radioimmunoassay developed in our laboratories was a trend toward higher values in older rats), but was
elevated in rats with renal ablation (P  0.05, compared[18]. Highly sensitive and specific antisera were raised
against BK. 125I-BK(Tyr8) was used as tracer. DesArg9- to 9-month-old SD and PKD; Table 1).
Plasma levels for prekallikrein and kallikrein did notBK displayed a cross-reactivity of 24%. All other nat-
ural kinin derivatives showed a cross-reactivity of less differ between the four groups of SD and PKD, but were
significantly higher in SD with remnant kidney (P than 1%.
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Table 1. Creatinine clearance, fractional sodium excretion, plasma renin activity, proteinuria, albuminuria, and systolic blood pressure in
SD, PKD, and SD with reduced renal mass
3 months 9 months
5/6 Nx
SD N  9 PKD N  15 SD N 18 PKD N  26 N  8
Creatinine clearance mL/min/100 g 0.650.04 0.540.02ac 0.510.01 0.420.02ac 0.430.02e
Fractional sodium excretion % 0.340.01 0.410.02 0.240.02 0.850.02c 1.080.1eg
Plasma renin activity ng Ang I/mL/h 4.040.47 3.970.36 4.030.28 2.470.23d 4.180.54g
Proteinuria mg/24 h 222 242 293 17516bd 18325f
Albuminuria mg/24 h 1.350.25 3.800.56c 2.680.44 16.461.28bd 14.501.92f
Systolic blood pressure mm Hg 1348 1394 1446 1494 1687eg
Values for creatinine clearance (mL/min/100 g), fractional sodium excretion (%), plasma renin activity (ng Ang I/mL/h), proteinuria (mg/24 h), albuminuria (mg/24
h), and systolic blood pressure (mm Hg) in 3- and 9-month-old SD and PKD and 9-month-old 5/6 nephrectomized SD. Data are presented as means  SEM; N 
number of animals.
a,bP  0.05, 0.01; 9-month-old SD and PKD compared to 3-month-old SD and PKD, respectively
c,dP  0.05, 0.01; 3- and 9-month-old PKD compared to age-matched SD
e,fP  0.05, 0.01; 5/6 Nx compared to 9-month-old SD
g,hP  0.05, 0.01; 5/6 Nx compared to 9-month-old PKD
Table 2. Values for prekallikrein, kallikrein, and bradykinin in SD, PKD and 5/6 Nx
3 months 9 months
5/6 Nx
SD N  9 PKD N  15 SD N 18 PKD N  26 N  8
Plasma prekallikrein U/mL 2.270.15 2.050.30 2.510.15 2.550.28 3.450.27cd
Plasma kallikrein U/L 2438 23810 25010 21910 35417cd
Urine prekallikrein mU/24 h 1216152 146474 50685a 71388a 31542d
Urine kallikrein mU/24 h 21826 26623 18530 68788c 17326d
Urine bradykinin ng/24 h 2.00.2 15.23.6b 5.81.1 131.024.0b 51.719.8e
Values for plasma prekallikrein (U/mL), plasma kallikrein (U/L), urine prekallikrein (mU/24 h), urine kallikrein (mU/24 h), and urine bradykinin (ng/24 h) in
3- and 9-month-old SD and PKD and 9-month-old 5/6 nephrectomized SD. Data are presented as means  SEM. N  number of animals.
a P  0.05 compared to 3-month-old SD or PKD
b P  0.05 compared to age-matched SD
c P  0.05; 5/6 Nx compared to 9-month-old SD
d P  0.05; 5/6 Nx compared to 9-month-old PKD
e P  0.06 compared to 9-month-old SD
0.05, compared to 9-month-old SD and PKD; Table 2). Effect of ramipril, HR 720, HOE 140, and
des-Arg9-[Leu8]-BK on renal function in PKDUrinary excretion of prekallikrein was reduced in 9-month-
old SD and PKD in comparison to young controls (P  No influence on creatinine clearance, fractional so-
0.05, respectively), whereas it did not differ between SD dium excretion, and urine volume was found in the differ-
and PKD. Urinary prekallikrein was further reduced in ent treatment groups (Table 3; data only shown for creat-
rats with reduced renal mass when compared to old PKD inine clearance).
(P  0.05). Urine excretion of kallikrein was markedly Plasma renin activity was markedly increased by rami-
elevated in old PKD compared to both young PKD and pril and HR 720 in all groups (P  0.05). Although this
old SD (P  0.05, respectively), whereas excretion in increase was numerically higher in ramipril-treated rats,
partially nephrectomized rats did not differ from 9-month- it did not statistically differ from animals treated with
old SD (Table 2). HR 720. Bradykinin-receptor blockade had no influence
Urinary bradykinin excretion was increased tenfold on PRA (Table 4).
in 3-month-old PKD and 30-fold in 9-month-old PKD Systolic blood pressure was not influenced in 3-month-
compared to age-matched SD (P  0.05, respectively). old SD and PKD (Fig. 1), whereas a significant decrease
In remnant kidney there was a trend toward higher bra- was observed in 9-month-old PKD and 9-month-old SD
dykinin levels in comparison to old SD (P  0.06). treated with ramipril and HR 720 (P  0.05). HOE
Chromatographic separation by HPLC of the urinary 140 and des-Arg9-BK had no effect on systolic blood
bradykinin fraction in 9-month-old PKD revealed a sec- pressure.
ond activity peak. This peak could be identified as de- Ramipril and HOE 140 significantly reduced protein-
sArg9-bradykinin, or T-kinin. Its concentration made uria in 3- and 9-month-old PKD, whereas ramipril and
up 13% of total bradykinin concentration in old PKD. HOE 140 had no influence on proteinuria in 3- and
T-kinin could not be demonstrated by HPLC in any of 9-month-old SD. HR 720 and des-Arg9-BK had no statis-
tically significant effect on the proteinuria in all groupsthe other investigated groups (data not shown).
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Table 3. Creatinine clearance before and after treatment with 2 mg/kg/day ramipril, 10 mg/kg/day HR 720, 2  200 g s.c. HOE 140,
or 2  250 g des-Arg9-[Leu8]-BK for four days
Ramipril HR 720 HOE 140 Des-Arg9-BK
Before After Before After Before After Before After
SD 3 N  10 0.710.03 0.630.02 0.740.03 0.680.03 0.640.04 0.590.02 0.690.06 0.680.05
PKD 3 N  10 0.590.02 0.630.02 0.580.04 0.600.02 0.590.03 0.610.03 0.570.04 0.580.05
SD 9 N  10 0.520.05 0.500.04 0.520.05 0.530.04 0.490.03 0.500.05 0.550.06 0.560.05
PKD 9 N  10 0.450.04 0.410.04 0.460.04 0.360.04 0.430.4 0.370.03 0.410.05 0.380.04
Values for creatinine clearance (mL/min/100 g) before and after treatment with 2 mg/kg/day ramipril, 10 mg/kg/day HR 720, 2  200 g s.c. HOE 140, or 2 
250 g des-Arg9-[Leu8]-BK for four days. Data are presented as meansSEM. N  number of animals.
Table 4. Plasma renin activity before and after treatment with 2 mg/kg/day ramipril, 10 mg/kg/day HR 720, 2  200 g s.c. HOE 140,
or 2  250 g des-Arg9-[Leu8]-BK for four days
Ramipril HR 720 HOE 140 Des-Arg9-BK
Before After Before After Before After Before After
SD 3 N  10 4.10.8 10724a 4.10.7 10.11.5a 4.20.8 4.80.3 3.60.9 5.21.4
PKD 3 N  10 3.90.5 5310.8a 4.10.4 15.81.7b 3.80.6 3.20.3 3.40.7 3.60.5
SD 9 N  10 4.10.4 13115b 4.50.5 13.01.6a 4.20.4 5.90.9 3.90.6 4.20.5
PKD 9 N  10 2.50.3 43.07.1b 2.50.3 8.31.6a 2.30.4 1.80.6 2.10.2 2.60.7
Plasma renin activity (PRA; ng Ang 1/mL/h) before and after treatment with 2 mg/kg/day ramipril, 10 mg/kg/day HR 720, 2  200 g s.c. HOE 140, or 2  250
g des-Arg9-[Leu8]-BK for four days. Data are presented as meansSEM. N  number of animals.
a P  0.05, b0.01, treatment effect compared to baseline value
Fig. 2. Effects of treatment with 2 mg/kg/day ramipril, 10 mg/kg/dayFig. 1. Effect of treatment with 2 mg/kg/day ramipril, 10 mg/kg/day
HR 720, 2  200 g SC HOE 140, or des-Arg9-BK for four days onHR 720, 2  200 g SC HOE 140, or des-Arg9-BK for four days on
proteinuria in 3- and 9-month-old SD and PKD rats (N  10, eachsystolic blood pressure in 3- and 9-month-old non-affected controls
group). Symbols are: () 9-month-old PKD; () 9-month-old SD; ()(SD) and polycystic kidney disease (PKD) rats (N  10, each group).
3-month-old PKD; () 3-month-old SD. Proteinuria was significantlySymbols are: () 9-month-old PKD; () 9-month-old SD; () 3-month-
reduced in 3- and 9-month-old PKD after treatment with ramipril andold PKD; () 3-month-old SD. Systolic blood pressure was significantly
HOE 140 (*P  0.05). Data are presented as means  SEM.reduced in 9-month-old PKD and SD after treatment with ramipril and
HR 720 (*P  0.05). Data are presented as means  SEM.
DISCUSSION
(Fig. 2). Similarly, albuminuria was significantly lowered
The present study demonstrates an age-dependent in-by ramipril and HOE 140 only in the 3- and 9-month-
crease in the activity of the renal KKS in the Han:SPRDold PKD rats (Fig. 3).
rat model of ADPKD, which paralleled the developmentRamipril had no influence on urinary excretion of pre-
of progressive renal failure.and kallikrein, whereas bradykinin excretion was mark-
In addition to a marked increase in urinary excretionedly increased (Table 5). HR 720 had no effect on these
of kallikrein and bradykinin, we showed that 9-month-parameters. Selective bradykinin-B2 receptor blockade
old PKD rats excrete T-kinin (desArg9-bradykinin). Thisincreased excretion of pre- and kallikrein as well as of
inflammatory peptide was first isolated in rat plasma [19,bradykinin, whereas B1 receptor blockade decreased ex-
cretion of all these molecules. 20], where it is cleaved from its biosynthetic precursor
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cantly decreased by treatment with ramipril and HOE
140. Angiotensin II receptor-blockade had no effect on
protein excretion, despite an equal suppression of the
RAS, as indicated by a significant increase of PRA and
a blood pressure reduction equal to ramipril. Thus, an
angiotensin II-independent pathway is responsible for
the proteinuria in PKD rats.
The role of the KKS with respect to proteinuria has
been studied in several experiments. Infusion of kalli-
krein into the renal artery of dogs causes proteinuria,
which can be reversed by the kallikrein inhibitor aproti-
nin [24]. Bradykinin and related kinins are potent stimu-
Fig. 3. Effect of treatment with 2 mg/kg/day ramipril, 10 mg/kg/day lators of phospholipase A2 and promote synthesis of ara-HR 720, 2  200 g SC HOE 140, or des-Arg9-BK for four days on
chidonic acid metabolites, including thromboxane A2albuminuria in 3- and 9-month-old SD and PKD rats (N  10, each
group). Symbols are: () 9-month-old PKD; () 9-month-old SD; () [25], which has been implicated in the pathogenesis of
3-month-old PKD; () 3-month-old SD. Albuminuria was significantly proteinuria in nephrotic syndrome [26]. The results of
reduced in 3-and 9-month-old PKD after treatment with ramipril and
the present study are consistent with experimental resultsHOE 140 (*P  0.05). Data are presented as means  SEM.
in rat models with normal or suppressed plasma renin
levels, where effects of ACE inhibition were related to
the interference with the KKS and not to inhibition of
T-kininogen. Urinary kinins in Sprague-Dawley rats angiotensin II production. Hutchison, Webster and Jaffa
have been identified as bradykinin, whereas kallidin, ar- showed that aprotinin could prevent the reduction of
ginyl-BK, or T-kinin could not been detected [21]. Our albuminuria induced by an ACE inhibitor in passive
study is, to our knowledge, the first demonstration of a Heymann nephritis [27]. The administration of phos-
urinary excretion of T-kinin in rats. phoramidon, which potentiates the kinin activity by inhi-
Previous experimental studies have reported a re- bition of the neutral endopeptidase, reduced albumin-
duced excretion of kallikrein in acute renal failure [22], uria to a similar extent as an ACE inhibitor. The
anti-glomerular basement membrane nephritis and am- angiotensin II receptor antagonist losartan, on the other
inonucleoside nephrosis [22], unilateral nephrectomy hand, decreased systolic blood pressure without any
[23], and diabetic nephropathy [12]. No kallikrein inhibi- change in albuminuria [28].
tors could be found in the urine of diseased animals, and In the present study only HOE 140 decreased protein-
it was concluded that tubular damage and/or destruction uria and albuminuria to the same extent than the ACE
of kallikrein-producing interstitial cells were the most inhibitor. This effect was independent from any influence
likely cause of decreased urinary kallikrein excretion. on systemic blood pressure and glomerular filtration rate.
Compared to rats with polycystic kidney disease, animals Selective B1 receptor blockade had no effect on urinary
subjected to renal mass reduction in our study excreted protein excretion, demonstrating that the B2-receptor
significantly less kallikrein and also less bradykinin. Be- plays a seminal role in the pathogenesis of proteinuria
cause creatinine clearance and proteinuria were virtually and albuminuria in PKD rats. This hypothesis is further
identical in these animals, our findings strongly suggest supported by the demonstration of T-kinin in urine of
disease-specific differences in the activity of the renal old PKD rats, given the fact that this molecule acts as
kallikrein-kinin-system. an agonist at the B2 receptor [29, 30], where it is 200-
The treatment of polycystic kidney rats with drugs times more active than at the B1 receptor.
that interfere at different levels with the RAS and the Both HOE 140 and ramipril increased urinary excre-
KKS provides important new insights in the pathophysi- tion of bradykinin, suggesting that the antiproteinuric
ology of PKD. Both ACE inhibitors and angiotensin II- effect of these drugs is mediated via stimulation of the
type 1 receptor antagonists markedly reduced systolic non-blocked B1 receptor. However, the mechanism of
blood pressure to the same degree in 9-month-old PKD increased bradykinin excretion fundamentally differs be-
rats, whereas bradykinin B1- and B2-receptor antago- tween icatibant and ramipril. Inhibition of the ACE,
nists had no effect. Systemic blood pressure regulation which is identical to kininase II, decreases bradykinin
in PKD therefore depends on the action of angiotensin degradation [31]. In contrast, no effect of ramipril on
II, despite a suppressed plasma renin activity in these urinary excretion of prekallikrein and kallikrein was ob-
animals [13]. The KKS obviously does not play a role in served, which confirms previous studies in other animal
blood pressure regulation in polycystic kidney disease models of chronic nephropathy [32, 33]. The increased
rats. kallikrein excretion observed after treatment with HOE
140 may be due to the inhibition of a recently describedIn contrast, proteinuria and albuminuria were signifi-
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Table 5. Urine prekallikrein, kallikrein, and bradykinin in 9-month-old PKD before and after treatment with 2 mg/kg/day ramipril, 10 mg/
kg/day HR 720, 2  200 g s.c. HOE 140, or 2  250 g des-Arg9-[Leu8]-BK for four days
Ramipril HR 720 HOE 140 Des-Arg9-BK
Before After Before After Before After Before After
Urine prekallikrein mU/24 h 79095 75668 83549 85273 74569 1228149b 85594 61478a
Urine kallikrein mU/24 h 68594 61987 71169 73496 77683 95689a 74982 53268a
Urine bradykinin ng/24 h 15319 39749b 12316 13637 12127 28937a 16823 1119a
Urine prekallikrein (mU/24 h), kallikrein (mU/24 h), and bradykinin (ng/24 h) in 9-month-old PKD (N  6, each treatment cycle) before and after treatment
with 2 mg/kg/day ramipril, 10 mg/kg/day HR 720, 2  200 g s.c. HOE 140, or 2  250 g des-Arg9-[Leu8]-BK for four days. Data are presented as means  SEM.
a P  0.05, b0.01; treatment effect compared to baseline value
therapy with enalapril and losartan on the rate of progression ofB2 receptor-mediated negative feedback loop of renal
renal injury in rats with 5/6 renal mass ablation. J Am Soc Nephrol
kallikrein expression [34]. 9:224–230, 1998
In summary, the present study demonstrates an age- 10. Legat FJ, Griesbacher T, Lembeck F: Mediation by bradykinin
of rat paw oedema induced by collagenase from Clostridium histo-dependent elevation of activity of the renal KKS in
lyticum. Br J Pharmacol 112:453–460, 1994Han:SPRD rats, which parallels the progression of renal 11. Pan KZ, Zuraw BL, Lung CC, et al: Bradykinin stimulates NF-	B
failure. The bradykinin B2-receptor is involved in the activation and interleukin 1
 gene expression in cultured human
fibroblasts. J Clin Invest 98:2042–2049, 1996pathogenesis of proteinuria in rat polycystic kidney dis-
12. Tscho¨pe C, Reinecke A, Seidl U, et al: Functional, biochemical,ease, independent from systemic blood pressure or creat- and molecular investigations of renal kallikrein-kinin system in
inine clearance. The antiproteinuric effect of ramipril in diabetic rats. Am J Physiol 277:H2333–H2340, 1999
13. Scha¨fer K, Gretz N, Bader M, et al: Characterization of thethis model is angiotensin II-independent and related to
Han:SPRD rat model for hereditary polycystic kidney disease.its influence on the renal KKS. Kidney Int 46:134–152, 1994
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